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Interferon (IFN) dramatically reduces both SIV and HIV-1 replication in vitro. However, we previously found that whereas
IFN treatment of SIV-infected cells results in a decrease in the level of viral RNA, IFN treatment of HIV-1-infected cells has
no effect on viral RNA expression but rather leads to a decrease in viral protein stability and a deregulation of polyprotein
processing (M. B. Agy, R. L. Acker, C. H. Sherbert, and M.G. Katze, Virology 214, 379–386, 1995). To more closely define the
stage of SIV replication adversely affected by IFN, we used several approaches, including PCR amplification, to examine the
effects of IFN on viral DNA synthesis and integration in MT4 and 174 3 CEM cells synchronously infected with SIV.
Unexpectedly, we found that IFN blocked the synthesis of viral DNA in SIV-infected cells but appeared to have no effect on
HIV-1 DNA synthesis. Using a p27 ELISA, we demonstrated that IFN had no effect on the attachment of SIV to MT4 cells.
Thus, our results indicate that IFN blocks an early stage of SIV replication, at a step between attachment and reverse
transcription. To our knowledge this is the first report to examine the effects of IFN on discrete stages of the SIV life cycle.
© 1998 Academic Press
INTRODUCTION
The antiviral activity of interferon (IFN) on primate
lentiviruses is of clinical interest, as IFN has been used
to treat HIV-1-infected individuals in an attempt to limit
virus replication and progression to AIDS. However, de-
spite numerous reports describing the antiviral activities
of IFN on HIV-1 replication in vitro (reviewed in Pitha,
1994), no clear benefits have been reported following the
administration of IFN to HIV-1-infected individuals (Fran-
cis et al., 1992; Poli et al., 1994). It appears that in vivo,
HIV-1 has successfully evolved strategies to avoid IFN’s
antiviral effects. Although considerable attention has
been focused on HIV-1 and IFN, virtually nothing is
known regarding the effects of IFN on SIV replication at
the molecular level. However, given the use of SIV infec-
tion of macaques as a model for HIV-1 infection, it is
important to understand the response of SIV to IFN
treatment. In addition, knowledge of the mechanisms
used by SIV to avoid the antiviral effects of IFN may
provide important clues into differences in SIV and HIV-1
replication, which may be important for a better under-
standing of the use of SIV as a model for HIV-1 disease.
The antiviral activity of IFN is mediated in part by
several IFN-induced enzyme systems. These include the
29-59 oligoadenylate synthetase, RNase L, the Mx pro-
teins, and the dsRNA-activated protein kinase, PKR
(Hovanessian, 1991; Staehli, 1990; Katze, 1995; Silver-
man, 1994; Gale and Katze, 1997). These IFN-induced
gene products appear to disrupt multiple levels of viral
gene expression, including viral mRNA stability, tran-
scription, and translation. In cell culture, IFN has a neg-
ative effect on HIV-1 replication, with blocks reported at
both early and late stages of the HIV-1 life cycle. Several
reports have suggested that IFN blocks the initiation of
reverse transcription and decreases proviral DNA accu-
mulation (Shirazi and Pitha, 1993, 1995; Baca-Regen et
al., 1995). Other studies have indicated that IFN specifi-
cally inhibits viral protein synthesis (Coccia et al., 1994)
or that IFN blocks the assembly and release of virions
(Hansen et al., 1995; Fernie et al., 1991). Our laboratory
previously reported that IFN disrupts HIV-1 replication at
a late stage of viral replication by decreasing viral protein
stability and disrupting polyprotein processing (Agy et
al., 1995). There is also evidence, however, that HIV-1
has evolved strategies to evade specific aspects of the
IFN-mediated antiviral response. For example, HIV-1 ap-
pears to be able to downregulate PKR activity through
the action of the tat gene product (Roy et al. 1990, 1991).
The Tat protein directly interacts with PKR, inhibiting both
the activation and the activity of the kinase (McMillan et
al., 1995; Brand et al., 1997). In addition, although Rnase
L is capable of degrading viral mRNAs (Zhou et al., 1993),
there is no evidence that HIV-1 replication can be inhib-
ited through this pathway (Agy et al., 1995). In contrast,
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our laboratory has shown that HIV-1 may encode a
mechanism to inhibit cellular protein synthesis by pro-
moting cellular mRNA degradation (Agy et al., 1990,
1996).
We previously reported that IFN blocks SIV replication
by inhibiting viral RNA accumulation, suggesting that IFN
affects HIV-1 and SIV replication by distinct mechanisms
(Agy et al., 1995). To expand on this finding, we have
attempted to further define the IFN-imposed molecular
block to SIV replication. Included in this study is the use
of PCR amplification to examine the effects of IFN on
viral DNA synthesis and integration in cells synchro-
nously infected with SIV. We found that IFN treatment led
to a block in the synthesis of viral DNA in SIV-infected
cells but appeared to have no effect on HIV-1 DNA
synthesis. Additional studies designed to examine a po-
tential block at an earlier step of SIV replication demon-
strated that IFN did not block virus attachment to the cell
surface. These findings suggest that IFN inhibits SIV
replication at a step following virus attachment, but be-
fore or at the reverse transcription of viral RNA.
RESULTS
Replication of SIV and HIV-1 is blocked at different
stages in IFN-treated cells
Previously, we found that in vitro, IFN treatment ad-
versely affects both SIV and HIV-1 replication (Agy et al.,
1995). In this study, we further analyzed the effects of IFN
on SIV replication to determine the stage of the SIV life
cycle inhibited by IFN. To ensure that we were able to
examine the effects of IFN on a single cycle of virus
replication, we synchronously-infected cells at a high
multiplicity of infection. As with our previous studies,
MT4 cells were chosen for this analysis since they re-
spond well to IFN treatment and are readily infected with
either SIV or HIV-1 (Agy et al., 1991, 1995). We began our
analysis by examining the effects of IFN on viral protein
production and viral RNA expression. Interferon-treated
or untreated MT4 cells were mock-infected or synchro-
nously infected with 0.1 TCID50 of SIVmac251 or HIV-1 LAI
per cell. Cell lysates were prepared on day 2 postinfec-
tion when nearly 100% of cells were infected as moni-
tored by indirect immunofluorescence. Using Western
blot analysis, we found that IFN treatment dramatically
reduced the level of viral proteins in both SIV-infected
and HIV-1-infected cells (Fig. 1). However, when viral
RNA expression was analyzed, IFN treatment led to a
decrease in the steady-state level of viral RNA only in
SIV-infected cells (Fig. 2). IFN treatment appeared to
have no effect on the level of HIV-1 RNA expression,
indicating that IFN affects these two viruses by distinct
mechanisms. These results were consistent with our
earlier findings (Agy et al., 1995) and suggested that IFN
blocked an early stage of SIV replication, thereby inhib-
iting the expression of viral RNA.
Integration of SIV DNA does not occur in IFN-treated
cells
Early stages of lentivirus replication include virus at-
tachment, entry, uncoating of viral RNA, reverse tran-
scription of viral RNA, integration of viral DNA into the
host genome, and the production of viral RNA transcripts
by RNA polymerase II (Clements and Zink, 1996). As an
initial experiment, we examined whether IFN treatment
had an effect on the integration of viral sequences into
FIG. 1. Interferon inhibits viral protein production in lentivirus-in-
fected cells. Western blot analysis of MT4 cell extracts prepared on day
2 postinfection. Cells were treated with IFN and infected as indicated
on bottom of each panel. Blots were probed with either pooled antisera
from SIV-infected macaques (lanes 1–4) or pooled antisera from HIV-
1-infected individuals (lanes 5–8). To control for protein loading, each
blot was stripped and reprobed with a monoclonal antibody specific for
b-actin. Positions of molecular weight standards are shown on the left
and viral proteins are indicated on the right.
FIG. 2. Interferon inhibits viral RNA expression in SIV-infected, but
not HIV-1-infected, MT4 cells. Northern blot analysis of total RNA
isolated from MT4 cells on day 2 postinfection. Blots were probed with
a [32P]CTP-labeled SIVmac239 DNA probe (lanes 1–4) or with a [
32P]CTP-
labeled HIV-1 pARV DNA probe (lanes 5–8). The lower portion of the
panel shows the same blots after stripping and reprobing with a
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) cellular gene
probe to control for RNA loading. Positions of 18S and 28S rRNAs are
shown on the left and viral RNAs are indicated on the right.
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the host genome. To detect the presence of proviral
DNA, high-molecular-weight DNA was collected and an-
alyzed for integrated viral sequences by PCR amplifica-
tion. Two alternative primer sets were used for this anal-
ysis, one specific for the viral LTR and another specific
for a region of the viral gag gene (Fig. 3). Interferon-
treated or untreated MT4 cells were mock-infected or
synchronously infected with SIVmac251 and high-molecu-
lar-weight DNA was isolated at 18 h postinfection. In the
absence of IFN treatment, both the LTR and the gag
primer sets yielded products from DNA isolated from
SIV-infected cells (Fig. 4A, lanes 2 and 5). In contrast, we
were unable to detect any amplified product from the
DNA of IFN-treated cells using either the LTR or the gag
primer sets (Fig. 4A, lanes 3 and 6). The lack of amplified
product from IFN-treated cells suggested that IFN inhib-
ited SIV replication at or before the integration of viral
DNA. To confirm that this result was not specific to MT4
cells, we also examined the effect of IFN on SIV replica-
tion in 174 3 CEM cells. Again, no amplified product was
observed from the DNA of IFN-treated cells using either
the LTR or the gag primer sets (Fig. 4B). This result
indicates that the observed effects of IFN on SIV repli-
cation are not cell line specific.
This analysis was next used to analyze the effect of
IFN on the integration of HIV-1 DNA. High-molecular-
weight DNA was collected from HIV-1-infected cells and
analyzed for viral sequences by PCR amplification. Inter-
feron-treated or untreated MT4 cells were mock-infected
or synchronously infected with HIV-1 and high-molecu-
lar-weight DNA was isolated at 18 h postinfection. In
contrast to our finding with SIV-infected cells, IFN ap-
peared to have no effect on the integration of HIV-1
proviral DNA into the chromosomal DNA of MT4 cells.
Using primer sets specific for the HIV-1 LTR, or a region
of the HIV-1 gag gene, integrated viral DNA could be
amplified from the DNA of both untreated and IFN-
FIG. 3. Oligonucleotide primers used for the detection of specific SIV and HIV-1 sequences by PCR. Arrows indicate sense (3) or antisense (4)
orientation for each primer. SIV and HIV-1 primer sets were chosen to amplify products unique to early steps in viral replication as described in the
text. Mitochondrial and GAPDH primer sets were used as internal PCR controls for the amplification of sequences present in low- or high-molecular-
weight DNA, respectively (Steinkasserer et al., 1995).
FIG. 4. Integration of SIV DNA does not occur in IFN-treated cells.
High-molecular-weight DNA was extracted from SIV- and mock-in-
fected cells and analyzed by PCR using either LTR (lanes 1–3) or gag
(lanes 4–6) primer sets (see text and Fig. 3 for details). Cells were
pretreated with media or IFN 18 h prior to infection as indicated.
Amplification of GAPDH (lanes 7–9) was included as an internal PCR
standard for high-molecular-weight DNA amplification. The positions of
relevant molecular weight standards are indicated on left. (A) MT4
cells; (B) 174 3 CEM cells.
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treated cells (Fig. 5). This result confirmed and extended
our earlier observation that IFN treatment did not reduce
the steady-state level of HIV-1 RNA (Fig. 2) and accen-
tuates the difference that IFN has on SIV and HIV-1
replication.
Reverse transcription of SIV RNA does not occur in
IFN-treated cells
Given our finding that integration of SIV DNA did not
occur in IFN-treated cells, we examined an earlier step in
viral replication, reverse transcription. For these studies,
low-molecular-weight DNA was collected and analyzed
for cytoplasmic viral replicative intermediates by PCR
amplification. Again, two alternative primer sets were
used. The LTR-specific primer set was used to detect
early steps in reverse transcription by amplifying se-
quences within the first region of viral DNA synthesized.
The gag primer set was used to detect full-length or
nearly full-length viral DNA. Interferon-treated or un-
treated MT4 cells were mock-infected or synchronously
infected with SIVmac251 and low-molecular-weight DNA
was isolated. At 18 h postinfection, IFN inhibited the
formation of both LTR and gag sequences. In SIV-in-
fected cells, little or no product was amplified from the
low-molecular-weight DNA of IFN-treated cells (Fig. 6A,
lanes 3 and 6), whereas a large amount of product was
amplified from the DNA of untreated cells (Fig. 6A, lanes
2 and 5). Again, we observed the same result using
174 3 CEM cells, demonstrating that this effect was not
specific to MT4 cells (Fig. 6B). These data indicate that
IFN inhibits SIV replication at or before the reverse tran-
scription of viral RNA.
Interferon does not block SIV attachment to MT4
cells
We next examined the possibility that the IFN-medi-
ated block to SIV replication was at a step prior to
reverse transcription, such as virion attachment to the
cell surface. This possibility was also suggested, in part,
by a report that IFN treatment downregulates CD4 ex-
pression (Nagai et al., 1997). To examine the effect of IFN
on SIV attachment, MT4 cells were pretreated with IFN,
CD4 mAb (10 mg/ml Leu3a Ab, Becton Dickinson), or
media and then mixed with serial dilutions of SIVmac251.
The CD4 mAb served as a positive control to monitor
inhibition of viral attachment. As expected, the amount of
p27 antigen bound to cells treated with CD4 Ab was
considerably less than the amount bound to untreated
cells (Table 1). In contrast, the amount of p27 antigen
bound to IFN-treated cells was essentially the same as
the amount bound to untreated cells. Thus, we con-
cluded that IFN does not block attachment of SIV to the
surface of MT4 cells. Although we did not examine the
level of CD4 in response to IFN treatment, it is possible
that, even in the presence of CD4 downregulation, the
level of expression remained sufficient for efficient at-
tachment of SIV.
FIG. 5. Interferon has no effect on the integration of viral DNA in
HIV-1-infected MT4 cells. High-molecular-weight DNA was extracted
from HIV-1-infected cells and analyzed by PCR using either LTR (lanes
1–3) or gag (lanes 4–6) primer sets. Amplification of GAPDH (lanes 7–9)
was included as an internal PCR standard for high-molecular-weight
DNA amplification. The positions of relevant molecular weight stan-
dards are indicated on the left.
FIG. 6. Reverse transcription of SIV RNA does not occur in IFN-
treated cells. Low-molecular-weight DNA was extracted from SIV- and
mock-infected cells and analyzed by PCR using either the LTR (lanes
1–3) or gag primer sets (lanes 4–6) (see text and Fig. 3 for details).
Amplification of mitochondrial DNA was included as an internal PCR
standard for low-molecular-weight DNA amplification. (A) MT4 cells; (B)
174 3 CEM cells.
TABLE 1
Interferon Does Not Block Attachment of SIVmac251 to MT4 Cells
Virus added (ml)
Cell-bound SIV p27 antigen (pg)
Medium IFN CD4 Ab
500 1333 1764 419
100 928 973 216
50 546 682 157
0 2 3 1
Note. Cells were pretreated with medium, IFN, or CD4 Ab and mixed
with dilutions of SIVmac251. After incubation and washing, cells were
lysed and p27 antigen measured by ELISA (see text for details).
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DISCUSSION
Based on our findings, it appears that IFN blocks an
early stage of SIV replication, at a step between attach-
ment and reverse transcription. One possibility is that
IFN may block SIV replication at a postattachment, virus–
cell membrane fusion step. Virus–cell fusion is mediated
by chemokine receptors (Deng et al., 1996; Dragic et al.,
1996; Alkhatib et al., 1996; Choe et al., 1996), and with the
recent revelation that the chemokine receptor CCR5 is
utilized by SIVmac239 (Chen et al., 1997; Marcon et al.,
1997), it may be interesting to examine whether the level
of CCR5 is affected by IFN treatment. However, even if
CCR5 expression is downregulated by IFN, a sufficient
level may remain to mediate efficient virus fusion. Alter-
natively, IFN may inhibit SIV replication by blocking the
postfusion release of functional RNA inside the cell (virus
uncoating). Since the Vpx and Vif proteins have both
been implicated in lentivirus uncoating processes (Gon-
calves et al., 1996; Yu et al., 1993), it may also be reveal-
ing to test the effect of IFN on the replication of vpx- or
vif-deficient SIV mutants.
To our knowledge this is the first report to examine the
effects of IFN on discrete stages of the SIV life cycle.
Other studies examining SIV and IFN have focused pri-
marily on the effects of IFN in SIV-infected animals. An
evaluation of the effects of IFN on virus replication and
disease progression in SIV-infected macaques found
that an elevated level of IFN-a in the serum is associated
with persisting antigenemia and that the IFN-a response
is unable to contain the initial burst of SIV replication
(Khatissian et al., 1996). It has also been reported that
IFN-a treatment suppresses SIV antigenemia in ma-
caques, but does not prolong the asymptomatic period or
survival time of the animals (Schellekens et al., 1996).
Thus, both SIV and HIV-1 appear to be able to evade the
IFN-mediated antiviral response in vivo despite being
severely inhibited by IFN in cell culture.
Interestingly, there are several reports describing an
IFN-mediated inhibition of HIV-1 reverse transcription,
leading to defects in proviral DNA synthesis (Shirazi and
Pitha, 1993, 1995; Baca-Regen et al., 1995; Kunzi and
Pitha, 1996). In contrast, we have been unable to detect
an early block to HIV-1 replication but have rather found
evidence that IFN inhibits HIV-1 replication at a late
stage (Agy et al., 1995). Consistent with this observation,
we found that HIV-1 proviral DNA was efficiently synthe-
sized and integrated into the chromosomal DNA of IFN-
treated MT4 cells (Fig. 5). Possibilities as to why our data
may differ from that of other groups include differences
in the HIV-1 strain, the assays used to measure viral
replication, and perhaps most importantly, whether stud-
ies were performed on synchronously infected cells.
Finally, our results indicate that IFN treatment affects
SIV and HIV-1 replication by different mechanisms,
blocking SIV replication at or before reverse transcrip-
tion, whereas HIV-1 replication is blocked at a later stage
of viral replication. In an attempt to define the viral gene
products responsible for this differential inhibition of vi-
rus replication, we are in the process of examining the
effects of IFN on HIV-1/SIV chimeric viruses (SHIVs).
Preliminary studies using one such virus, SHIV-4 (con-
taining the SIVmac239 core and HIV-1 tat, rev, and env
genes) (Li et al., 1992), indicate that this SHIV has a
distinct response to IFN that is unlike either SIV or HIV-1.
Although IFN inhibited SHIV RNA expression, reverse
transcription and integration of proviral DNA did not
appear to be affected. Based on our findings in this
report, it may also be of interest to examine a recently
described SHIV construct that contains the HIV-1 reverse
transcriptase in a SIV background (Uberla et al., 1995).
Additional analyses of how IFN mediates this early inhi-
bition of SIV replication in cell culture may give insight
into how SIV and HIV-1 are able to evade the effects of
the IFN system in vivo.
MATERIALS AND METHODS
Cells, virus infection, and interferon treatment
CEM (Foley et al., 1965), MT4 (Harada et al., 1985),
174 3 CEM (Hoxie et al., 1988), and C8166 cells
(Salahuddin et al., 1983) were obtained from the AIDS
Reagent repository. Cells were maintained in RPMI 1640
medium containing 10% fetal bovine serum and 10 mM
HEPES, pH 7.3. HIV-1 LAI (Barre-Sinoussi et al., 1983) and
SIVmac251 (Daniel et al., 1985) stocks were prepared by
collecting culture supernatants from infected CEM and
MT4 cells, respectively. Viral TCID50 was estimated by
infecting multiple samples of C8166 cells with serial
10-fold dilutions of HIV-1 LAI or SIVmac251. After 7–14
days, the infected cells were monitored for cytopathic
effect. The dilution at which one-half of the cultures
exhibited cytopathic effect was the TCID50. These data
were confirmed by p24 or p27 ELISA. MT4 cells were
treated with media or media containing human IFN-a/b
at 1000 units/ml 18 h prior to infection. To examine the
effects of IFN on a single viral replication cycle, cells
were synchronously-infected at a high multiplicity of in-
fection. Virus was added to the cells at a multiplicity of
0.1 TCID50/cell, which rapidly resulted in infection of
nearly 100% of the cells as measured by indirect immu-
nofluorescence. Trypan blue exclusion was used to mon-
itor cell viability and all studies were done in cultures
that contained at least 85% viable cells.
Protein and RNA analysis
For Western blot analysis, cells were disrupted in
ice-cold Triton X-100 lysis buffer (1% Triton X-100, 10 mM
Tris–HCl, pH 7.5, 50 mM KCl, 1 mM dithiothreitol, 2 mM
EDTA, 1 mM MgCl2, 0.2 mM phenylmethanesulfonylfluo-
ride, and 100 mg/ml aprotinin). Proteins were resolved by
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SDS–PAGE and transferred to nitrocellulose filters. Pri-
mary antibody was pooled sera from HIV-1-infected pa-
tients or SIV-infected macaques. Bound conjugated an-
tibodies were detected by enhanced chemiluminescence.
Total RNA was isolated from cells by the guanidi-
nium thiocyanate–phenol–chloroform extraction method
(Chomczynski and Sacchi, 1987). For Northern blot anal-
ysis, RNA was electrophoresed on a denaturing 1% aga-
rose gel and transferred to nylon filters as described
(Thomas, 1980). Blots were probed with a [32P]CTP-la-
beled SIVmac239 DNA probe (Kestler et al., 1990) or with a
[32P]CTP-labeled HIV-1 pARV DNA probe (Luciw et al.,
1984).
DNA isolation and PCR amplification
Low- and high-molecular-weight DNA was prepared
as previously described (Hirt, 1967). For PCR amplifica-
tion, 100 ng of low- or high-molecular-weight DNA was
subjected to 35 rounds of amplification in a reaction
volume of 25 ml. PCR primer sets used for this analysis
are described in detail under Results and Discussion.
Amplified products were separated on agarose gels and
visualized by ethidium bromide staining. Southern blot
analysis was used to confirm that products amplified
using viral DNA-specific primers contained viral se-
quences.
Attachment assay
MT4 cells were pretreated with media, media contain-
ing 1000 units/ml IFN-a/b, or media containing 10 mg
Leu3a Ab (anti-CD4, Becton Dickinson). Serial dilutions
of SIVmac251 were then mixed with the cells and incu-
bated for 4 h at 4°C. After extensive washing in cold
media, cells were lysed in Triton X-100 buffer and SIV p27
antigen concentration was measured by ELISA (RETRO-
TEK SIV-1 p27 Antigen ELISA, Cellular Products Inc.).
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